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ABSTRACT
Background: Although anxiety disorders are prevalent in older adults, randomized controlled trials of treatment
effectiveness for late-life anxiety are scarce and have focused primarily on the effectiveness of psychotherapeutic
interventions. However, recent findings suggest that in some cases, pharmacological treatment may be more
beneficial for late-life anxiety disorders. As yet, there have been no systematic studies investigating prognostic
factors for the outcome of cognitive behavioral therapy (CBT) and pharmacotherapy for late-life anxiety. The
objective of the present study was to study long-term treatment outcomes and to explore differential predictors
for both short-term and long-term treatment outcomes of sertraline and CBT for late-life anxiety disorders.
Methods: Participants of a randomized controlled trial (RCT) comparing sertraline and CBT for the treatment
of late-life anxiety were contacted one year after completing their treatment, so that predictors for both short-
term and long-term treatment outcome could be established.
Results: Sertraline showed a greater reduction of symptoms than CBT on anxiety (Hamilton Anxiety Rating
Scale; HARS) andworry (WorryDomainQuestionnaire) ratings at one-year follow-up. The strongest predictor
for short-term CBT outcome was poor perceived health, explaining 40% of the variance in post-treatment
residual gain scores on the HARS. The strongest predictor for long-term CBT outcome was neuroticism,
explaining 20% of the variance in residual gain scores at one-year follow-up. Analyses revealed no significant
predictors for treatment outcome in sertraline participants.
Conclusions: Our study suggests that long-term use of sertraline might be more beneficial for late-life anxiety
than a 15-week CBT program. Poor perceived health and neuroticism are predictive of less improvement after
CBT in anxious older adults. Implications of these findings are discussed.
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Introduction
Although anxiety disorders are among the most
prevalent mental disorders among older adults
(Flint, 1994), randomized controlled trials of treat-
ment effectiveness for late-life anxiety are scarce
and have focused primarily on the effectiveness of
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psychotherapeutic interventions, more specifically,
of cognitive behavioral therapy (CBT; Mohlman,
2004). Recently, our research group completed
the first randomized controlled trial (RCT) of
the effectiveness of individual format CBT versus
an SSRI (sertraline) for the treatment of late-life
anxiety disorders (Schuurmans et al., 2006).
Although both treatments resulted in statistically
significant improvement in outcome scores, effect
sizes (Cohen’s d, calculated as (Mpre-treatment –
Mpost-treatment)/standard deviationpooled; Cohen,
1988) for CBT were relatively small (post-
treatment mean d= 0.34), whereas effect sizes for
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sertraline were in the large range (post-treatment
mean d= 1.00). This is in concordance with a
recent meta-analytic comparison of psychological
versus pharmacological interventions for late-life
anxiety (Pinquart and Duberstein, 2007), which
concluded that the available studies indicate that
pharmacotherapy shows larger average treatment
effects than psychological interventions. However,
follow-up measurements for our RCT were
restricted to a three-month follow up. This is
quite a short period, considering the fact that
mixed-age population studies of CBT tend to find
that CBT has enduring effects that reduce the risk
for symptom return after termination of treatment.
A similar effect is not found for treatment with
an SSRI: after discontinuation of treatment, most
patients eventually experience recurring anxiety
symptoms (Hollon et al., 2006).
As yet, there have been no systematic studies
investigating prognostic factors for the outcome of
CBT for late-life anxiety. Treatment studies of late-
life anxiety to date have primarily included older
adults who are relatively young, well educated, and
physically healthy (Stanley et al., 2009). It has
been implied that this fact might have led to an
overestimation of treatment effect in the available
studies to date, and that CBTmight be considerably
less effective in the older old, the less educated and
frail elderly. Since cognitive functions are assumed
to deteriorate with age, and acquisition of new
skills is an assumed prerequisite for the effectiveness
of CBT (Mohlman, 2005), it is possible that
the “older old” (commonly defined as those aged
75 years and over) would benefit less from CBT. In
summary, age, educational level and health factors
are believed to have an impact on treatment effect
in anxious older adults. However, this hypothesis
awaits scientific testing. Neuroticism was found to
be predictive of a detrimental naturalistic long-term
outcome of anxiety disorders in older adults by
our research group (Schuurmans et al., 2005). For
the present study, we hypothesized that neuroticism
might also affect treatment outcome for late-life
anxiety disorders.
In mixed-age populations, studies on the
prediction of treatment outcome for anxiety
disorders are relatively scarce and often provide
conflicting results. Documented predictors of a less
favorable outcome of psychological interventions
for anxiety in mixed-age populations include a
longer duration of illness (Scheibe and Albus,
1997), older age (Scheibe and Albus, 1997), initial
severity of anxiety (e.g. Seivewright et al., 1998),
agoraphobic avoidance (e.g. Scheibe and Albus,
1997), pre-treatment depression (e.g. Scholing
and Emmelkamp, 1999) and certain personality
dimensions or disorders (e.g. Scholing and
Emmelkamp, 1999). Documented predictors of
a less favorable outcome of drug treatment for
anxiety in younger and mixed-age populations seem
to be similar to some extent, including such factors
as higher levels of symptom severity (Solvason
et al., 2003), a longer duration of symptoms (e.g.
Slaap and den Boer, 2001), depressive symptoms
(Stein et al., 2001), agoraphobic avoidance (e.g.
Slaap and den Boer, 2001) and certain personality
disorders or traits (Slaap and den Boer, 2001).
Since CBT and sertraline are fundamentally
different treatment modalities and since we found
some differences in degree of effectiveness between
CBT and sertraline for the treatment of late-life
anxiety (Schuurmans et al., 2006), we set out to
explore differential predictors of treatment effect
in this population. In this manner we might also
be able to determine which characteristics are
important when trying to decide on the treatment
of choice for a particular patient.
The present study aims to examine the long-term
outcome of CBT and sertraline for the treatment
of late-life anxiety. Additionally, this study aims
to investigate differential predictors for treatment
outcome of sertraline and CBT for late-life anxiety
disorders. For the present study, participants of the
original RCT were contacted and measured one
year after completing CBT and sertraline treatment,
so that predictors for both short-term and long-term
treatment outcome could be investigated. Since
information on the prediction of treatment outcome
of anxiety in older adults is virtually absent, ours
is an exploratory study. The choice of predictor
variables was based on frequently voiced opinions
in the research literature on anxiety in older adults
and on predictor variables found in anxious mixed
age populations. Predictor variables included age,
educational level, duration of symptoms, depressive
symptoms, agoraphobic symptoms, neuroticism
and perceived health.
Methods
The treatment study
Participants for the original randomized controlled
trial (Schuurmans et al., 2006) included 84 adults,
aged 60 years and over, with a principal DSM-
IVTR (American Psychiatric Association, 1994)
diagnosis of generalized anxiety disorder (GAD),
panic disorder (with or without agoraphobia),
agoraphobia without a history of panic disorder
or social phobia. Patients excluded from the
trial were those with an organic condition that
provided a contra-indication for the use of selective
serotonin reuptake inhibitors (SSRIs), current use
of antidepressant medication, a comorbid diagnosis
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Assessed for eligibility (n=160) 
Excluded  (n=89) 
 
Did not meet inclusion criteria  
(n=45) 
Refused to participate 
(n= 31) 
Other reasons  
(n= 0) 
Randomly allocated to wait-list (n=13) 
(not a part of the current study) 
Analyzed  (n=30) 
 
Non-completers were not analyzed, 
as our study was primarily focused 
on predictors of treatment effect 
Lost to follow-up  (n= 5) 
    
Allocated to CBT (n=42) 
Received CBT (n=39) 
Completed CBT (30) 
Refusal after randomization (n=3) 
Treatment drop-out (n=9) 
Reasons for drop-out 
Treatment was found to be too 
demanding or confronting (N=2) or too 
time-consuming (N=2), participants did 
not agree with the treatment rationale 
(N=5) and spontaneous remission of 
symptoms (N=4). 
Lost to follow-up  (n= 3) 
    
Allocated to sertraline (n=29) 
Received sertraline (n=25) 
Completed sertraline (n=17 ) 
Refusal after randomization (n=4) 
Treatment drop-out (n=7) 
Reasons for drop-out 
long-term illness (N=1) 
deceased before starting medication 
(N=1), side effects (N=4), anticipated 
side effects before actually 
starting medication (N=1), and 
spontaneous remission of symptoms 
(N=1).
Analyzed  (n=17) 
 
Non-completers were not analyzed, 
as our study was primarily focused 
on predictors of treatment effect 
Allocation 
Analysis 
Follow-up 
Enrollment 
Randomisation 
(n=71) 
Figure 1. Flow chart of enrollment in the RCT.
of alcohol dependency, current participation in
psychotherapy and a history of psychosis or
cognitive impairment as indicated by clinical
impression and a score of less than 26 on the
Mini-mental State Examination (Folstein et al.,
1975). Individuals stabilized on benzodiazepines
and their therapists were instructed not to change
their dose or type of medication for the duration
of the study. Medication use during treatment was
monitored by the therapist in each session and
recorded on a form to ascertain that the use of
benzodiazepines was not altered. Individuals with
comorbid depression, dysthymia, or other anxiety
disorders were not excluded from participation, as
long as their principal diagnosis was GAD, panic
disorder, agoraphobia or social phobia. Principal
diagnosis was defined as the most severely disabling
disorder at the present time. Participants were
recruited from 2000 to 2003 through media
announcements, distribution of information leaflets
in pharmacies and general practice clinics, and
among referrals for treatment to five community
mental health centers and out-patient clinics in
five cities in the western and southern part of
the Netherlands. All participants were selected
on the basis of a structured diagnostic interview
(SCID 2.0; First et al., 1999), administered by
psychologists who had received extensive training
in this instrument.
Over a 3.5 year recruitment period, 160 subjects
received a diagnostic interview, 115 (72%) of
whom fit the inclusion criteria and were invited
to participate in the research. Thirty-one patients
(27%) refused to participate before providing
preliminary data. Eighty-four participants remained
who were randomized into the study. All parti-
cipants read and signed an informed consent form
prior to being randomly assigned to one of three
study arms: 15 weeks of CBT (n= 42), sertraline
(n= 29) or a 15 week-waiting period (n= 13).
Figure 1 provides a flow chart of enrollment in
the original trial. Randomization procedures were
as follows: one envelope was filled with 62 labels
stating “CBT”, 62 labels stating “sertraline” and
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26 labels stating “wait-list”.We consciously planned
for fewer subjects in the wait-list group because
we assumed that it would show no effects, as
is the case in comparable treatment studies (e.g.
Wetherell et al., 2003). This distribution would
yield maximum power to detect differences between
CBT and sertraline, while still allowing for enough
power to differentiate between the active treatment
and the wait-list subsamples (Woods et al., 1998).
After completing the screening procedure for a
given participant, the principal researcher would
blindly take one label out of the envelope, which
would then be excluded from further randomization
procedures. However, even though we allowed for
a lengthy recruitment period and great efforts
were made to contact potential participants, we
could only assign 84 participants and the remaining
66 labels were not used in the randomization
procedure, which is why sample sizes are unequal.
Trained psychologists and a trained research
assistant performed assessment interviews at pre-
test, post-test, and at three-month follow-up. Those
who performed these assessments were not involved
in the delivery of treatment. Participants in the
CBT arm of the trial were treated individually by
an experienced and certified behavior therapist in
15 weekly one-hour sessions. In total, 11 CBT
therapists took part in the project. Most therapists
had ample experience in working with standardized
treatment protocols in treatment trials and most
therapists were experienced in the treatment of older
adults. There was a separate CBT protocol for each
anxiety diagnosis, in which examples, information
leaflets and the specification of exercises were
adapted. However, the main ingredients of CBT
(relaxation, exposure and cognitive restructuring)
were similar across protocols. Treatment protocols
for CBT were derived from prevailing treatment
protocols of panic disorder (Clark and Salkovskis,
1986), GAD (Borkovec and Costello, 1993) and
social phobia (Scholing and Emmelkamp, 1995)
in mixed-age populations which were adapted for
use with older adults (our CBT protocol consisted
of 15 sessions, allowing more attention to psycho-
education and repeated explanation and revision
of new information and newly learned coping
skills). Participating therapists took part in regular
supervision meetings, which were led by certified
supervisors for behavior therapy. Therapists were
repeatedly and explicitly instructed to contact their
project supervisor if they felt that they needed to
deviate from the protocol. Their supervisor would
then talk through the problem at hand to ensure
that therapists would adhere to the protocol.
In the sertraline arm of the trial, patients were
treated by a psychiatrist or a resident-psychiatrist
in eight 20-minute sessions over a period of
15 weeks. In total, three psychiatrists and six
resident psychiatrists participated in the project.
The protocol for sertraline included a dosage
schedule adapted for older adults, in which the
starter dose was lower (25 mg) and the dosage
was built up more gradually than in the customary
procedure (up to a minimum dose of 100 mg
which had to be reached within four weeks and a
maximum dose of 150mg on the basis of tolerability
and lack of clinical response). Medication was
maintained during one-year follow-up, except when
the participant explicitly requested the medication
to be tapered off.
Ten (12%) of the 84 patients refused to parti-
cipate in the trial immediately after randomization,
four of whom were assigned to sertraline, three to
CBT and three to the wait-list group. Seventeen
(23%) of the remaining 74 participants dropped
out of the trial before completing CBT (n= 9),
sertraline (n= 7) or wait-list study arms (n= 1),
culminating in a total attrition rate of 32% (27 of
the initial sample of 84 participants). There were
no significant differences in attrition rates across
treatment groups. One participant randomized to
sertraline switched to venlafaxine in one of the
first weeks of treatment due to adverse side-effects
and was excluded from outcome analysis. For
completer analyses, data from 56 participants were
available: 30 completed CBT, 17 completed the
sertraline study arm, and nine stayed on the wait
list. Another four participants failed to return their
pre-test questionnaires although they did complete
the HARS interview; one was assigned to sertraline,
two to CBT and one to the wait-list group.
The present study
SAMPLE
Analyses for the present study were based on the 47
completers in the active treatment arms of the RCT.
Participants in the wait-list group were excluded
from the present study, since they were referred to
one of the active treatment arms after completing
the 15-week waiting period. Measurements took
place before and after completing the treatment
arms, and at follow-up, one year post-treatment.
Age at pre-test varied from 61 to 81, with a
mean age of 70. Age of onset was “early” (below
the age of 60) in 28 participants (59.6%) and
duration of anxiety varied from two months to
63 years, with a mean duration of 29 years. Thirty-
seven participants (78.7%) suffered from some form
of chronic somatic disease. The chronic diseases
that were most common among participants were
hypertension (n= 14; 29.8%), arthritis (n= 10;
21.3%) and cardiovascular diseases (n= 10;
21.3%). Twenty-three participants (48.9%) used
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Table 1. Baseline characteristics of the sample
CBT SERTRALINE
VARIABLE (n= 30) (n= 17)
............................................................................................................................................................................................................................................................
Age at pre-test M (SD) 70.60 (6.52) 69.35(5.88)
Duration of symptoms (yrs) M (SD) 27.85 (25.20) 30.47(23.52)
Female n (%) 21 (70.0) 12 (70.6)
Married n (%) 17 (56.7) 13 (76.5)
Education
Low n (%) 14 (46.7) 5 (29.4)
Medium n (%) 6 (20.0) 7 (41.2)
High n (%) 10 (33.3) 5 (29.4)
Main diagnosis
GAD n (%) 8 (26.7) 7 (41.2)
Panic disorder1 n (%) 14 (46.7) 8 (47.0)
Agoraphobia2 n (%) 4 (13.3) 1 (5.9)
Social phobia n (%) 4 (13.3) 1 (5.9)
Chronic medical disorder n (%) 26 (86.7) 11 (64.7)
Benzodiazepine use n (%) 14 (46.7) 9 (52.9)
BAI pre-test M (SD) 19.09 (12.09) 22.90 (13.19)
HARS pre-test M (SD) 14.48 (8.00) 17.86 (8.22)
Depressive symptoms pre-test M (SD) 20.63 (10.77) 24.71 (9.97)
Worry symptoms pre-test M (SD) 24.37 (20.81) 24.36 (12.94)
Agoraphobic symptoms pre-test M (SD) 36.50 (18.69) 37.03 (15.35)
Neuroticism pre-test M (SD) 7.37 (3.32) 9.10 (2.36)
Perceived health M (SD) 15.63 (5.54) 13.69 (4.81)
1With or without agoraphobia.
2Without a history of panic disorder.
BAI=Beck Anxiety Inventory; CBT= cognitive behavior therapy; GAD= generalized anxiety disorder;
HARS=Hamilton Anxiety Rating Scale.
one or more benzodiazepines. Further information
regarding the distribution of baseline characteristics
across the two treatments can be found in Table 1. A
comparison on all pre-test demographic and clinical
variables, including the distribution of principal
diagnosis and severity of anxiety symptoms at
baseline using χ2 tests and ANOVA’s demonstrated
no significant differences (Table 1).
Measures of treatment outcome
Outcome was assessed at post-treatment and at
one-year follow-up. Pre-test, post-test and follow-
up measurements consisted of self-report measures
and a structured interview. The interview consisted
of the Hamilton Anxiety Rating Scale (HARS;
Hamilton, 1959; Cronbach’s α = 0.82). The HARS
was performed by two members of the research
group. Inter-rater agreement on the HARS was
measured in the initial stages of the project.
Weighted κ was 0.58, constituting moderate inter-
rater agreement. Self-report measures included
the Beck Anxiety Inventory (BAI; Beck and
Steer, 1990; Cronbach’s α = 0.93) and the Dutch
adaptation of the Worry Domain Questionnaire
(WDQ; Rijsoort et al., 1999; Cronbach’s α = 0.92).
Items related to work situations in the WDQ
were omitted because they were not considered
appropriate for an older population. Depressive
symptoms were measured with the Centre for
Epidemiological Studies Depression Scale (CES-D;
Radloff, 1977; Cronbach’s α = 0.90).
Predictor variables of treatment outcome
Predictor variables of treatment outcome were
measured at pre-test and included age, educational
level, duration of symptoms in years, depressive
symptoms as measured with the CES-D; Radloff,
1977), agoraphobic symptoms as measured with
the Agoraphobia Scale (AS; Ost, 1990; Cronbach’s
α = 0.96), neuroticism as measured with the
neuroticism subscale of the Eysenck Personality
Questionnaire-revised (EPQ-R; Eysenck et al.,
1985; Cronbach’s α = 0.78) and perceived health
(a subscale of the MOS-20; Stewart et al., 1988;
Cronbach’s α = 0.86). Items related to driving a car
were omitted from the analysis of the AS, since a
large proportion of participants did not own a car
or no longer held a driver’s license.
Data analysis
T tests and χ2 tests were used to compare
participants assigned to CBT and sertraline on all
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predictor variables measured at pre-test. Therapy
outcome at one-year follow-up was assessed with
paired t tests and ANCOVAs on the outcome
scores of follow-up measurements using pre-test
scores as a covariate for all patients who completed
treatment (Gibbons et al., 1993). Both completer
analyses and intent to treat (ITT) analyses for
long-term treatment outcome are presented. A
conservative Last Observation Carried Forward
method (LOCF), in which the available pre-
treatment score is regarded as the subsequent post-
treatment score, was used to account for missing
data in patients who dropped out of therapy
without completing post-treatment assessments.
Two measures of clinically significant change were
assessed: (1) treatment response for anxiety, defined
as an improvement of 20% on two measures of
anxiety (BAI and HARS) and high end state
functioning for anxiety, defined as a score of
less than 10 on both the BAI and the HARS
(which equals a score within the normal range).
The 20% reduction criterion of treatment response
in a composite measure of both self-report and
interview-rated instruments is common in the
treatment literature of anxiety in older adults (e.g.
Barrowclough et al., 2001). Rates of treatment
response and high end state functioning at one-year
follow-up were determined and compared between
treatment groups using χ2 analyses.
Predictor analyses were conducted for two
moments in time: at post-treatment and at one-
year follow-up. To investigate the prognostic value
of predictor variables measured at pre-test for
treatment outcome of anxiety, residual gain scores
(Steketee and Chambless, 1992) were used for
the HARS, which was chosen as the main
outcome variable. The residual gain score has
several advantages over raw outcome scores or
change scores, because it takes into account both
pre-test differences and measurement error, by
using the following formula: residT2= z2−z1× r12
(where residT2 is the residual gain score at post-
test (T2); z2 is the standardized score at post-
test (T2); z1 is the pre-test standardized score;
and r12 is the correlation between z1 and z2).
A series of linear regression analyses were run,
using residual gain scores on the HARS at post-
treatment and follow-up as outcome variables. Data
for CBT and sertraline completers were analyzed
separately. First, all predictor variables were
entered individually in a univariate linear regression
model. Next, all predictors showing a significant
effect in the univariate regression analyses were
entered in a forward multivariate regression
model, to see which of the variables showed an
independent contribution to treatment outcome
and to establish the magnitude of this contribution
(the amount of variance in residual gain scores
explained).
Missing values were imputed by means of
last observation carried forward. When baseline
measures were missing (e.g. due to incompletely
filled out questionnaires) we have imputed data by
means of amissing value analysis in SPSS using data
on gender, age and the main outcome measures as
predictors.
Results
Loss to follow-up and differences between
treatment groups
For post-treatment analyses, data were available
from 47 participants who completed the CBT
(n= 30) and sertraline (n= 17) treatment arms.
Eight participants refused to cooperate with
assessment at one-year follow-up, leaving a sample
of 39 (25 CBT and 14 sertraline) participants who
were included in follow-up analyses. Those who
were lost to follow-up scored lower on the perceived
health scale at baseline than those who participated
in one-year follow-up assessments (t(42)= 2.09,
p < 0.05). No other significant differences between
participants and those lost to follow-up were found
for any of the demographic or predictor variables
included in this study. Also, ANCOVAs on the post-
treatment outcome measures using pre-test scores
as a covariate did not show differences in treatment
effectiveness between participants and those lost
to follow-up. Sertraline use was maintained during
follow-up in at least 7 of 14 participants (50%).
Unfortunately, data on sertraline use during follow-
up are missing in 4 of 14 participants (28.6%).
During follow-up, seven participants (3 CBT and 4
sertraline participants) sought additional treatment
at the research centre, four of whom received an
alternative psychopharmacological treatment and
three of whom received CBT.
A comparison on all pre-test demographic and
predictor variables using t tests and χ2 tests
demonstrated no significant differences between
those randomized to CBT or sertraline at baseline.
However, sertraline completers did have a higher
rate of comorbid depression at baseline than CBT
completers (44.4% versus 10.0%; χ2(1)= 7.56,
p < 0.05). Sertraline completers did not differ
from CBT completers on any of the other variables
included in the study.
Treatment outcome at one-year follow-up
Paired t tests were performed to assess within-
treatment effects for each group between pre-test
and one-year follow-up. Table 2 presents means and
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Table 2. Means and standard deviations for completers on all outcome measures at pre-treatment, post-
treatment and one-year follow-up by study arm.
CBT SERTRALINE
PRE- POST- POST-
TREATMENT TREATMENT FOLLOW-UP PRETREATMENT TREATMENT FOLLOW-UP
............................................................................................................................................................................................................................................................................................................................
BAI 19.09 (12.09) 13.65 (12.66) 15.83 (12.56) 22.90 (13.19) 14.15 (10.48) 15.06 (13.05)
HARS 14.48 (8.00) 10.33 (6.97) 9.77 (6.76) 17.86 (8.22) 11.00 (8.67) 8.57 (7.69)
CES-D 20.64 (10.77) 17.16 (11.69) 18.58 (12.99) 24.71 (9.97) 17.69 (8.87) 16.87 (6.57)
WDQ 24.37 (20.81) 17.18 (18.26) 18.68 (19.32) 24.36 (12.94) 14.94 (9.89) 13.65 (9.15)
CBT= cognitive behavior therapy; BAI=Beck Anxiety Inventory; HARS=Hamilton Anxiety Rating Scale; CES-D=Centre for
Epidemiological Studies Depression Scale; WDQ=Worry Domain Questionnaire.
standard deviations for all outcomemeasures at pre-
treatment, post-treatment and one-year follow-up
by treatment arm. Table 3 presents t and p values,
effect size estimates and percentage of change over
time by treatment.
At one-year follow-up, improvement from
baseline scores was significant on all outcome
measures for sertraline completers. For CBT
completers, improvement from baseline scores was
significant on the BAI, the HARS and the WDQ,
but not on the CES-D. Effect size estimates were
calculated as the difference between mean pre-and
one-year follow-up scores divided by the pooled
standard deviations from baseline and follow-up
scores (Cohen’s d). In general, effect sizes for
CBT at one-year follow-up remained relatively
small (mean d at one-year follow-up= 0.35 versus
post-treatment mean d= 0.42; Schuurmans et al.,
2006) whereas effect sizes for sertraline remained in
the large range (one-year follow-up mean d= 0.92
versus post-treatment mean d= 0.94; Schuurmans
et al., 2006).
For a direct comparison of the effectiveness
of treatment arms, we conducted ANCOVAs
on the follow-up scores of all completers
with pre-test scores as the covariate. Results
favored sertraline on the HARS (F(1,45)= 4.24,
p< 0.05, η2 = 0.09), but not on the BAI
(F(1,45)= 2.30, p= 0.14, η2 = 0.05), the CES-
D (F(1,45)= 2.74, p= 0.11 η2 = 0.06) or the
WDQ (F(1,45)= 3.76, p= .06 η2 = 0.08). At post-
treatment, rates of treatment response (57%
for sertraline versus 44% for CBT participants)
and high end state functioning (47% for
sertraline and 48% for CBT participants) did
not differ significantly between treatment groups
(Schuurmans et al., 2006). At one-year follow-
up, 67% of sertraline participants and 39% of
CBT participants could be classified as treatment
responders (χ2 (1)= 2.39, p= 0.12). Fifty-seven
percent of sertraline participants and 44% of CBT
participants fit criteria for high end state functioning
at one-year follow-up (χ2(1)= 0.62, p= 0.43).
However, ITT analyses showed no significant
differences with regard to the relative effectiveness
of CBT versus sertraline at one-year follow-up,
although the ANCOVA on the HARS reached near
significance (F(1,66)= 3.52, p= 0.07, η2 = 0.05).
Table 3. Paired t tests and p values, effect size estimates and percentage of change over time by treatment
arm.
CBT SERTRALINE
PRE-TREATMENT-1-YEAR PRE-TREATMENT-1-YEAR
FOLLOW-UP (n= 25) FOLLOW-UP (n= 14)
t p d % df t p d % df
...........................................................................................................................................................................................................................................................................................................................
BAI 2.28 <.05 0.26 17 29 3.42 <0.01 0.60 34 16
HARS 5.27 <0.001 0.64 33 29 5.10 <.0001 1.15 52 16
CES-D 1.88 0.25 0.17 10 29 3.64 <0.01 0.95 32 16
WDQ 3.94 <0.01 0.32 23 29 3.74 <0.01 0.97 44 16
CBT= cognitive behavior therapy; BAI=Beck Anxiety Inventory; HARS=Hamilton Anxiety Rating Scale; CES-D=Centre for
Epidemiological Studies Depression Scale; WDQ=Worry Domain Questionnaire.
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Table 4. Predictors of residual gain scores on the HARS for CBT and sertraline participants
PREDICTOR VARIABLES POST-TREATMENT 1-YEAR FOLLOW-UP
..............................................................................................................................................................................................................................................................................
CBT r2 β p r2 β p
Age at pre-test 0.11 0.34 0.07 0.10 0.31 0.13
Educational level 0.02 −0.12 0.53 0.01 −0.11 0.62
Duration of symptoms 0.00 0.03 0.88 0.00 −0.04 0.87
Depressive symptoms 0.21 0.46 < 0.05 0.07 0.26 0.22
Agoraphobic symptoms 0.01 0.11 0.57 0.04 0.20 0.36
Neuroticism 0.26 0.51 < 0.01 0.22 0.47 < 0.05
Perceived health 0.40 −0.63 < 0.001 0.18 −0.43 < 0.05
Sertraline
Age at pre-test 0.00 0.07 0.79 0.03 0.19 0.53
Educational level 0.03 −0.18 0.50 0.01 0.08 0.78
Duration of symptoms 0.06 −0.25 0.36 0.02 −0.13 0.68
Depressive symptoms 0.00 0.06 0.84 0.01 −0.09 0.76
Agoraphobic symptoms 0.09 0.29 0.31 0.03 0.17 0.56
Neuroticism 0.00 0.00 0.99 0.00 0.01 0.98
Perceived health 0.05 −0.22 0.45 0.01 −0.10 0.76
HARS=Hamilton Anxiety Rating; CBT= cognitive behavior therapy.
Predictors of treatment outcome for CBT
Regression analyses on post-treatment scores of
the HARS using pre-test scores on the HARS as
an independent variable revealed that 57.3% of
the variance in post-test scores on the HARS was
explained by the pre-test (β= 0.77, p < 0.001).
Regression analyses on residual gain scores at post-
treatment revealed several significant predictors
for an unsuccessful treatment outcome for CBT
participants. These included comorbid depressive
symptoms, neuroticism and lower perceived health
scores (Table 3). A multiple forward regression
analysis incorporating these predictors revealed
that only lower perceived health had a significant
independent contribution to the prediction of an
unsuccessful treatment outcome (β=−0.63, p <
0.01), explaining 40.0% of the variance in residual
gain scores.
At one-year follow-up, 45.3% of the variance
in HARS scores was explained by the pre-test
scores (β= 0.69, p < 0.001). Regression analyses
on residual gain scores at one-year follow-up again
revealed lower perceived health and neuroticism as
significant predictors for an unsuccessful treatment
outcome (Table 3). Comorbid depressive symptoms
were not found to be predictive for long-term
treatment outcome. In contrast to post-treatment
analyses, a multiple forward regression analysis
incorporating perceived health and neuroticism
revealed that only neuroticism had a significant
independent contribution to the prediction of an
unsuccessful treatment outcome at one-year follow-
up (β=−0.63, p < 0.01), explaining 22.0% of the
variance in residual gain scores.
Predictors of treatment outcome for
sertraline
Regression analyses on post-treatment HARS
scores using pre-test scores as an independent
variable revealed that 36.5% of the variance in post-
treatment HARS scores was explained by the pre-
test (β= 0.60, p < 0.05). Regression analyses on
HARS scores at one-year follow-up revealed that
only 13% of the variance in follow-up HARS scores
was explained by the pre-test (β= 0.36, p= 0.20).
Regression analyses on residual gain scores at one-
year follow-up revealed no significant predictors for
treatment outcome.
Discussion
Treatment outcome at one-year follow-up
Data comparing short-term effectiveness of CBT
and sertraline for late-life anxiety, described in a
previous report by our research group (Schuurmans
et al., 2006), revealed higher effect sizes and a better
result on worry symptoms for sertraline. Long-
term treatment outcome reflects similar results
with sertraline showing more improvement on
worry symptoms, but also on anxiety symptoms
as measured with the HARS. Effect sizes for
sertraline remained in the moderate to large
range (Cohen’s d= 0.60–1.62), while effect sizes
for CBT were small to moderate (Cohen’s
d= 0.22–0.70). This is in concordance with a
recent meta-analysis by Pinquart and Duberstein
(2007) on the effectiveness of psychological versus
pharmacological interventions, which concluded
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that pharmacological interventions seem to be
more effective in reducing anxiety in late life
than psychological interventions. However, ITT
analyses revealed no significant differences with
regard to long-term treatment effect. Although ITT
analyses may provide a conservative estimate, since
respondents were regarded as unchanged when
post-treatment scores were missing, it is important
to take into account that only those who complete
treatment may benefit more from sertraline than
from standard individual CBT.
Variables predicting treatment response
First of all, we would like to stress the exploratory
nature of our analyses with regard to the prediction
of treatment effect. As our sample was relatively
small and no previous studies have focused on the
prediction of treatment effect for late-life anxiety,
results with regard to these analyses should merely
be interpreted as plausible hypotheses to be tested
and replicated in larger samples or meta-analytic
research.
Our study provides support for several predictors
for the treatment outcome of CBT for late-life
anxiety, including comorbid depressive symptoms,
poor perceived health and neuroticism. Poor
perceived health seems to be predictive for
treatment failure in CBT, but not in sertraline
participants. This is a rather remarkable finding,
since poor health is generally held to be detrimental
to drug treatment effect. In fact, health issues in
older adults are the reason why several papers have
argued that psychological interventions constitute
the preferred mode of treatment for late-life anxiety
disorders (e.g. Mohlman, 2004). With regard to
the meaning of perceived health for the prediction
of treatment effect, a recent publication on factors
related to the self-perception of health sheds an
interesting light on this subject. In this study,
subjective health was found to be highly correlated
with self-report measures of subjective well-being
(life satisfaction, anxiety and depression) and
the sense of coherence, while correlations with
objective health-related variables were insubstantial
(Schneider et al., 2004). The sense of coherence
(SOC) is defined as a personality orientation that
“expresses the extent to which a person has a
pervasive, enduring feeling of confidence that (1)
the stimuli deriving from one’s internal and external
environments in the course of living are structured,
predictable and explicable (comprehensibility), (2)
resources are available to meet the demands posed
by these stimuli (manageability), and (3) these
demands are challenges, worthy of investment
and engagement (meaningfulness). Thus, SOC
should be a personality orientation that facilitates
coping with the health problems and disabilities of
old age, influencing subjective health perception”
(Schneider et al., 2004). These findings imply
that perceived health in older adults may be
a reflection of certain coping mechanisms and
psychological factors rather than an accurate
measure of objective health. Therefore, we should
be careful in concluding from our study that
disabled or chronically ill older adults with anxiety
disorders should not be referred to CBT.
Neuroticism was found to be the strongest
predictor for an unsuccessful long-term treatment
outcome. In a previous study, our research group
also found neuroticism to be predictive of a
natural long-term persistent outcome of anxiety
disorders in late-life (Schuurmans et al., 2005) and
it has been found to be related to the onset and
prognosis of mood and anxiety disorders in mixed-
age populations in several other studies (for an
extensive review of these studies, see Clark et al.,
1994).However, there has been considerable debate
over the meaning of the construct of neuroticism
in recent years. Neuroticism is generally regarded
as a personality trait, reflecting negative affectivity
(Clarke et al., 1994). In a recent article, Ormel
and colleagues pointed out that neuroticism might
simply reflect a person’s characteristic level of
distress over a protracted period of time (Ormel
et al., 2004). They argue that although self-report
measures of neuroticism may be used to mark a
vulnerable subgroup of patients who are at risk for
onset and chronicity of all sorts of psychopathology,
these measures do not actually offer an explanation
for this vulnerability. In our study, neuroticism was
measured by a subscale of the EPQ-R (Eysenck
et al., 1985). When investigating the items of this
subscale, it appeared to us that high neuroticism
scores may also reflect the tendency to perceive
oneself as a generally nervous and unstable person,
i.e. the tendency to perceive one’s symptoms as an
unchangeable character trait rather than as some-
thing thatmay be cured. To illustrate, example items
of the EPQ-R include “Do you regard yourself as a
nervous person?” and “Do you regard yourself as a
worrisome person?”. This might reflect a disbelief
in the possibility of change which may hinder
both spontaneous remission as well as the effective
psychological treatment of anxiety in late life.
Unfortunately, we were not able to discern
any predictors for either short-term or long-term
treatment outcome in sertraline participants. Some
of the documented predictors of treatment effect
found in mixed-age populations, such as duration
of symptoms for both CBT and pharmacological
treatment outcome (Scheibe and Albus, 1997;
Slaap and den Boer, 2001; Stein et al., 2001;
Solvason et al., 2003) and depressive symptoms for
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pharmacological treatment outcome (Stein et al.,
2001) were not found to be related to outcome in
our study. It should be noted, however, that some of
the analyses reported in this study may have failed
to reach statistical significance due to small sample
size, as discussed below.
Limitations
The main limitations to the present study were
its lack of power due to small sample size,
differences in sample size between treatment arms
and loss of subjects for follow-up measurements.
Our randomization procedures were unsuccessful
as a result of unforeseen recruitment problems. As
a consequence, our study is not as persuasive as it
might have been if other randomization procedures
had been used, and certain predictors of treatment
effect may have been overlooked.
Although treatment results for sertraline in
this study seem promising, it should be noted
that all analyses in the present study were based
on completers (and those who participated in
the one-year follow-up) and that the use of
sertraline was maintained during follow-up in
at least 50% of sertraline participants, which
may have biased the comparison with CBT.
The long-term treatment gains mentioned in this
study should probably be ascribed to ongoing
treatment with sertraline. Continuance of sertraline
obviously carries certain disadvantages, such as
side-effects, although available studies of SSRIs for
depression and anxiety suggest similar tolerance
for SSRIs between older and younger adults
(e.g. Schneider et al., 2003; Lenze et al., 2005;
for a comprehensive overview of the side-effects
experienced by participants in the current treatment
study see Schuurmans et al., 2006). Also, older
adults tend to prefer psychological interventions
over drug treatments (van Schaik et al., 2004).
Furthermore, since the review board for medical
ethics did not grant us permission to allocate older
adults to a placebo study group, we cannot be
certain if treatment effect should be solely attributed
to the use of sertraline. However, the fact that
treatment results were maintained during a one-
year follow-up period makes it less plausible that
treatment effect is attributable to a placebo-effect
(Quitkin et al., 1987).
The long-term outcome of CBT showed less
optimistic results and we found no evidence of
an improved effectiveness over time. However, the
fact that our sample consisted of patients with
mixed anxiety disorders (mainly panic disorder
and GAD) and the fact that we did not include
assessment instruments specific to each disorder,
might have masked some of the treatment gains
from CBT. Although overall levels of anxiety only
moderately improved due to CBT, disorder-specific
symptom levels, such as frequency of panic attacks
and agoraphobic avoidance in our participants with
panic disorder, may have improved on a larger scale.
A significantly higher proportion of completers
in the sertraline treatment group suffered from a
comorbid depression. This is a result of selective
drop-out of participants in the CBT group (those
who had a comorbid depression were more likely
to drop out of CBT, see Schuurmans et al., 2006).
One might argue that improvement potential was
simply much higher in the sertraline treatment arm.
However, analyses with regard to differences on
outcome measures that were used for the study did
not show any significant differences between the
active treatment groups at baseline. Furthermore,
the differences found in the ANCOVA were based
on anxiety measures, not measures of depression
(HARS and WDQ).
No significant predictors of long-term sertraline
treatment effect were found in this investigation.
However, some of the predictors of drug treatment
effect reported in studies in mixed-age populations
were not included in the present study, such
as the presence of certain early side effects
(Solvason et al., 2003) and unfamiliarity with
psychopharmacological treatment (Stein et al.,
2001; Solvason et al., 2003). Also, the sertraline
group was markedly smaller than the CBT group,
resulting in a substantial difference in statistical
power to detect possible predictors of treatment
effect between the two study arms.
It should be noted that participants were not re-
quested to refrain from seeking additional treatment
during follow-up and seven participants received
additional treatment during follow-up at one of our
research centers, which may have biased our results.
Due to ethical considerations, participants could
not be requested to refrain from seeking additional
treatment or to maintain sertraline use during
follow-up, although maintenance of sertraline was
advised for at least one year.
Finally, it should be noted that assessors were not
blind to the treatment arms.
Recommendations and conclusions
Long-term outcome analyses of the present study
suggest that the long-term use of sertraline might
be more beneficial for the treatment of late-life
anxiety than an individually delivered, standard
CBT program of 15 sessions. Our results clearly call
for more studies on the pharmacological treatment
of late-life anxiety with SSRIs, involving larger
samples and a placebo group to establish true drug
response. For anxious older adults, the barrier to
seeking psychotherapeutic treatment from a mental
health care specialist is high, due to logistical
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problems (e.g. transportation), the psychological
strain involved in psychotherapy and the stigma
on psychiatric care for this generation. Drug
treatment with SSRIs may provide a solution to
this problem, as in most cases the treatment can
take place in a primary care setting. However,
as stated before, anxious older adults tend to
be reluctant to take medication for psychological
problems (van Schaik et al., 2004). The need
for treatment fidelity is stressed by the lack of
difference in long-term treatment effect in our
ITT analyses. Also, older adults have a higher
chance of suffering from a somatic disease that
provides a contra-indication for the use of SSRIs
and recent findings indicate that SSRIs may carry
the same heightened risk for accidents, falls,
fractures and cognitive decline as has been reported
for benzodiazepines (e.g. French et al., 2006).
Therefore, the development of more effective, low-
threshold psychological interventions remains a
necessity. Short-term psychological interventions
provided at home or in a primary care setting
may be more cost-effective and, moreover, more
accessible to this particular group, than a relatively
long and arduous cognitive behavioral treatment
in a psychiatric setting. One recent study provides
support for a short-term CBT intervention for late-
life anxiety in primary care (Stanley et al., 2009),
but more research is needed to develop effective
primary care interventions for this population and
to adapt common psychological interventions for
anxiety disorders successfully to older adults.
Poor perceived health and neuroticism may be
predictive of CBT treatment failure in anxious
older adults. Future comparative treatment studies
of CBT and SSRIs for late-life anxiety should
include other possible predictors of treatment
effect, such as the presence of certain (early)
side effects, unfamiliarity with drug treatment,
comorbid medication use and medical conditions.
Also, findings from the present study should be
replicated in a larger sample or meta-analysis of
previous trials. This could provide more definite
cues for clinical practice to establish the preferred
type of treatment for each individual.
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Editor’s note
Although this paper technically could be said to report information from a randomized controlled trial
and was not registered in a RCT register as required by International Psychogeriatrics, it has been accepted
because the original trial was done prior to 2003 and the paper itself represents a recontacting of the
RCT participants rather than a clear report of an unregistered RCT. However, individuals contemplating
submission of RCT related data to International Psychogeriatrics should not take the acceptance of this article
to be any kind of precedent. Those intending to submit RCT data to International Psychogeriatrics should
read the Instructions to Contributors thoroughly, and where they have queries in relation to the suitability
of their articles for possible publication in International Psychogeriatrics, they should contact the editor prior
to submission.
